CANF
Can-Fite BioPharma Ltd. · Healthcare
3.06
0.33%(-0.01)
Prev. Close3.22
5.23%(+0.16)
Pre-marketLast Updated: — ET
52W L: $2.9552W H: $36.40
$3.05
CHG-1.53 (-33.41%)
H$4.62
L$2.79
VOL1.3M
CANF (1h)
Can-Fite BioPharma Ltd. · Healthcare
Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 study of Piclidenoson for the treatment of osteoarthritis in dogs.
RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for the year ended December 31, 2025 and early 2026.
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market Ramat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Israeli Patent Office has allowed its patent application No.
Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.
RAMAT GAN, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 795,869 American Depositary Shares (ADSs), having an exercise price of $9.
Can-Fite BioPharma Ltd. (AMEX: CANF) shares are up on Wednesday following the company's announcement that its drug, Namodenoson, successfully met the primary endpoint in a Phase 2a study for pretreated pancreatic cancer patients.
Regev Guy
director
0 SH @ $0.00
2026-03-18
Regev Guy
director
16 SH @ $2826.14
2017-02-08
Regev Guy
director
200 SH @ $241.47
2020-06-15
Regev Guy
director
2,166 SH @ $25.21
2023-08-01
Regev Guy
director
2,166 SH @ $26.56
2024-08-07
Regev Guy
director
16,000 SH @ $2.18
2026-04-25
Bornstein Yoseph
director
200 SH @ $241.47
2021-06-22
Bornstein Yoseph
director
2,166 SH @ $25.21
2023-08-01